In promoting the reopening of schools this fall, Trump administration officials have, at times, inaccurately described the evidence on how COVID-19 affects children.
White House trade adviser Peter Navarro has promoted the “astonishing” results of an observational study that found hydroxychloroquine was associated with lower mortality for patients hospitalized for COVID-19. But the study has limitations, and multiple randomized controlled trials have found the drug is not beneficial to hospitalized patients.
At the White House, the Health and Human Services secretary left the misleading impression that the FDA’s decision to revoke its emergency use authorization of hydroxychloroquine and chloroquine for COVID-19 “removes a potential barrier” and makes it easier to access the drugs. The FDA’s action does the opposite.
At a June 8 press conference, a World Health Organization scientist confusingly suggested that asymptomatic transmission of the coronavirus is “very rare” — a statement that many scientists found problematic, and which some politicians and those on social media seized upon as evidence that certain public health measures were not necessary.